Amphastar Pharmaceuticals, Inc.: FDA regulatory profile

Amphastar Pharmaceuticals, Inc. appears in 6 indexed U.S. FDA records: 6 drug-shortage entries (from 6 openFDA source rows), naming 6 distinct products. Latest dated event: a shortage record dated 2026-08-18. Observations run 2012-01-01 to 2026-08-18 — 5343 days, 12 dated records across 5 calendar years, busiest 2026 with 6. Shortages: 6 current, averaging 1 package lines each across 7 FDA therapeutic categories, 6 strengths, 25 package NDCs and 2 brand names. 5 related firms and 8 adjacent shortage entries are linked below, each by a shared shortage entry, substance or therapeutic category. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. By year: 2026 (6), 2022 (1), 2018 (2), 2017 (1), 2012 (2). Shortage entries include Atropine Sulfate Injection (Current, since 2012-01-01, 1 lines), Dextrose Monohydrate 50% Injection (Current, since 2022-01-13, 1 lines), Lidocaine Hydrochloride Injection (Current, since 2012-02-22, 1 lines) and Lorazepam Injection (Current, since 2018-05-03, 1 lines).